TENX (Tenax Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by TENX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Declan Doogan | Director | Buy | — | — |
| 2026-09-15 | THOMAS R STAAB II | Chief Financial Officer | Buy | — | — |
| 2026-09-15 | Christopher Thomas Giordano | CEO | Buy | — | — |
| 2026-09-08 | ADAR1 Capital Management, LLC | 10%+ Owner | Buy | — | — |
| 2026-09-02 | Daniel Schneeberger | 10%+ Owner | Buy | — | — |
| 2026-08-24 | Daniel Schneeberger | 10%+ Owner | Buy | — | — |
| 2026-07-14 | Christopher Thomas Giordano | CEO | M | — | — |
| 2026-05-13 | THOMAS R STAAB II | Chief Financial Officer | A | — | — |
| 2026-02-03 | THOMAS MCGAULEY | Interim CFO | M | — | — |
| 2026-01-13 | June Sherie Almenoff | Director | A | — | — |
| 2026-01-13 | GERALD T PROEHL | Director | A | — | — |
| 2026-01-13 | Declan Doogan | Director | A | — | — |
| 2026-01-13 | Michael H. Davidson | Director | A | — | — |
| 2026-01-13 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2026-01-13 | Robyn Hunter | Director | A | — | — |
| 2026-01-13 | Christopher Thomas Giordano | CEO | A | — | — |
| 2025-12-10 | Stuart Rich | Chief Medical Officer | Buy | — | — |
| 2025-12-05 | Stuart Rich | Chief Medical Officer | Buy | — | — |
| 2025-11-20 | June Sherie Almenoff | Director | Buy | — | — |
| 2025-11-20 | Christopher Thomas Giordano | CEO | Buy | — | — |
| 2025-11-19 | THOMAS MCGAULEY | Interim CFO | Buy | — | — |
| 2025-11-19 | June Sherie Almenoff | Director | Buy | — | — |
| 2025-07-03 | June Sherie Almenoff | Director | A | — | — |
| 2025-07-03 | Michael H. Davidson | Director | A | — | — |
| 2025-07-03 | Robyn Hunter | Director | A | — | — |
| 2025-07-03 | GERALD T PROEHL | Director | A | — | — |
| 2025-07-03 | Declan Doogan | Director | A | — | — |
| 2025-05-20 | Christopher Thomas Giordano | CEO | A | — | — |
| 2025-05-20 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2024-12-12 | June Sherie Almenoff | Director | A | — | — |
| 2024-12-12 | Declan Doogan | Director | A | — | — |
| 2024-12-12 | Christopher Thomas Giordano | CEO | A | — | — |
| 2024-12-12 | Robyn Hunter | Director | A | — | — |
| 2024-12-12 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2024-12-12 | Michael H. Davidson | Director | A | — | — |
| 2024-12-12 | GERALD T PROEHL | Director | A | — | — |
| 2024-05-21 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2024-05-21 | Christopher Thomas Giordano | CEO | A | — | — |
| 2022-09-23 | Stuart Rich | Chief Medical Officer | G | — | — |
| 2022-08-12 | Declan Doogan | Director | G | — | — |
| 2022-06-10 | Christopher Thomas Giordano | CEO | A | — | — |
| 2022-06-10 | Robyn Hunter | Director | A | — | — |
| 2022-06-10 | June Sherie Almenoff | Director | A | — | — |
| 2022-06-10 | GERALD T PROEHL | Director | A | — | — |
| 2022-06-10 | Stuart Rich | Chief Medical Officer | A | — | — |
| 2022-06-10 | Declan Doogan | Director | A | — | — |
| 2022-06-10 | Michael H. Davidson | Director | A | — | — |
| 2022-05-19 | Steven Boyd | Director | MIXED | — | — |
| 2021-12-06 | Stuart Rich | Chief Medical Officer | G | — | — |
| 2021-08-11 | Declan Doogan | Director | G | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,524,151 | — |
| — | 10%+ Owner | 5,436,447 | — |
| — | Director | 55,274 | — |
| — | CEO | 17,324 | — |
| — | Chief Financial Officer | 15,675 | — |
| — | Interim CFO | 7,000 | — |
| — | Chief Medical Officer | 6,460 | — |
| — | Director | 3,986 | — |
| — | Director | 2,881 | — |
| — | Director | 2,519 | — |
| — | Director | 2,449 | — |
| — | Director | 2,330 | — |
| — | Director | 1,667 | — |
| — | Chief Executive Officer | 40 | — |
| — | CFO | 22 | — |
| — | Director | 4 | — |
| — | Director | 2 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TENX quote page; the site-wide leaderboard is on the insider transactions hub.